TMCnet News
Research and Markets: PharmaPoint: Human Immunodeficiency Virus (HIV) - Global Drug Forecast and Market Analysis to 2023 for the $15 Billion IndustryResearch and Markets (http://www.researchandmarkets.com/research/7x37nr/pharmapoint) has announced the addition of the "PharmaPoint: Human Immunodeficiency Virus (HIV) - Global Drug Forecast and Market Analysis to 2023" report to their offering. Global HIV Therapeutics Market Value Will Crawl to Almost $15.3 Billion by 2023. The value of the Human Immunodeficiency Virus (HIV) treatment market will increase marginally from just over $14 billion in 2013 to approach $15.3 billion by 2023, representing a low Compound Annual Growth Rate (CAGR) of 0.9% across the nine major markets of the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, and China. While the overall market size will not undergo major changes, the treatment landscape is expected to experience a paradigm shift towards integrase inhibitor drugs and single-tablet regimens (STRs). This shift will be most pronounced in the US, as financial austerity measures remain a primary barrier to growth in the other countries. Moritz Herrmann, Ph.D., says: The market growth will mainly be driven by the introduction of novel drugs, such as STRs with improved tolerability, a reduced pil burden or increased efficacy, and an increasing number of people living with HIV who are treated with antiretroviral therapy (ART). However, due to patient and physician awareness of HIV often being limited, there have been low diagnosis rates, increased disease transmission, and delayed ART administration. During the forecast period, market growth will be limited by patent expirations of several key products, such Gilead Sciences' Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate [TDF (News - Alert)]). Furthermore, several countries, such as Germany, China and Brazil, will promote the use of more affordable generic drugs over branded products. However, The report notes that the launches of several STRs, such as ViiV's Triumeq (dolutegravir/abacavir/lamivudine) and Gilead's Quad 2 (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide [TAF]), will help to offset the impact of generics over the next few years. Herrmann continues: Despite these new drugs, the HIV treatment space is still plagued by a range of environmental barriers, such as low patient awareness of the disease, and the social stigma that is associated with it in most countries. Lack of access to medicines and the high cost of therapy still represent major hurdles that must be overcome in order to fully address the global HIV epidemic, the analyst concludes. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Unmet Need and Opportunity 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook 11 Appendix Companies Mentioned
For more information visit http://www.researchandmarkets.com/research/7x37nr/pharmapoint
View source version on businesswire.com: http://www.businesswire.com/news/home/20151214006087/en/ |
